Overview

Comparative Study of Flecainide CR and Placebo in the Early Treatment of Atrial Fibrillation.

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the efficacy of flecainide controlled release (CR) in the prevention of recurrent AF during 9 months of active treatment compared to placebo in patients with only one documented AF episode.
Phase:
Phase 4
Details
Lead Sponsor:
MEDA Pharma GmbH & Co. KG
Collaborator:
3M
Treatments:
Flecainide